Rapid Saliva Protein Test
The Rapid Saliva Protein Test (RSPT), from Medusa 19, provides results on the spot in 15 minutes. It is a lateral flow test (LFT) using a simple saliva sample to indicate the immune response to infection, particularly in patients who do not know they have an active SARS-CoV-2 infection and have no specific symptoms.
The RSPT is a simple, non-invasive, on the spot test indicating the immune response to infection from SARS-CoV-2, the virus underlying COVID-19. The LFT requires a simple saliva sample, a comfortable and non-invasive collection process, providing rapid results within 15 minutes.
Developed in the UK and Spain, the test indicates a user's immune response to SARS-CoV-2.
Relative sensitivity of 92%, relative specificity of 98% and 97% accuracy.View Product
Avacta Antigen Test
Medusa 19 has entered into a distribution agreement with Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, for its COVID-19 rapid antigen test that is currently under development.
This agreement provides Medusa 19 with exclusive distribution rights to consumers and non-exclusive distribution rights to businesses.
The test will indicate whether an individual has the COVID-19 infection and is intended to provide a result within minutes.
See more on the Avacta site or via our news section.Coming Soon